Does testosterone therapy cause acne? @dermangelo explains

What did @dermangelo actually say?

A dermatologist on TikTok laid out the acne risk picture for transmasculine people on testosterone, citing a prevalence range of "50 to 88%" and noting that "about a fifth" of those cases will be severe. They added that acne typically starts between four and six months on testosterone, can evolve over two years, and in some people persists beyond ten years. They also flagged that having a testosterone level "higher than the median" is a risk factor for developing acne vulgaris specifically.

The creator was careful to acknowledge the data limitations upfront, saying "we don't have great data about it." That kind of epistemic honesty is genuinely rare in health TikTok, and it matters here because the evidence base really is thin.

Does the science back this up?

Mostly, yes, though the confidence intervals on those prevalence numbers are wide enough to drive a truck through. The 50-88% figure appears consistent with the published literature, but that range should itself tell you something: we're talking about small, retrospective studies with different follow-up periods and outcome definitions.

A 2019 retrospective study by Wierckx et al. in the Journal of Sexual Medicine documented acne as one of the most common adverse effects in transmasculine individuals on testosterone, with rates varying substantially by formulation and dose. Turrion-Merino et al. (2015, JAMA Dermatology) reported acne in the majority of transgender men on testosterone therapy, with severe cases in a meaningful subset. More recently, Liszewski et al. (2018, International Journal of Women's Dermatology) reviewed dermatologic conditions in transgender patients and confirmed the pattern: acne onset in the first year, severity varying by serum testosterone levels. The "higher than median" testosterone level claim as a risk factor has support in the endocrinology literature, where supraphysiologic androgen levels are consistently tied to worse acne outcomes regardless of the population studied.

What did they get wrong (or right)?

Honestly, they got most of this right. The prevalence range is defensible. The timeline of four to six months for onset aligns with what the literature describes. The two-year evolution window is reasonable. The "over 10 years" persistence claim is harder to verify in the trans-specific literature, but chronic acne vulgaris lasting a decade or more is documented in cisgender populations on long-term androgen therapy, so it's a plausible extrapolation, not a fabrication.

The one area worth scrutinizing is the severity estimate. Saying acne will be severe in "about a fifth" of those who develop it implies a reasonably precise figure, but the studies underpinning this are mostly small and retrospective. Giltay and Gooren (2000, Journal of the American Academy of Dermatology) reported severe acne in a subset of transgender men, but sample sizes were under 100 in most early studies. The creator appropriately hedged by acknowledging weak data at the start, which partially covers this. Still, presenting "a fifth" as if it's a settled statistic is slightly stronger than the evidence warrants.

The advice to see a dermatologist if acne develops, and the reassurance that treatment is possible while staying on testosterone, is accurate and clinically appropriate.

What should you actually know?

If you're on testosterone and developing acne, this is not a fringe side effect. It is probably the most common dermatologic consequence of testosterone therapy in transmasculine people, and it can affect both the face and body including the chest and back. The fact that it can become severe means early treatment matters. Waiting it out is not always the right call.

The testosterone level point is practically useful. If you're developing significant acne, it is worth having a conversation with your prescriber about where your levels are sitting. Supraphysiologic levels are not necessary for gender-affirming benefit in most cases, and running higher than needed increases acne risk without a clear upside.

Treatment options are real. Topical retinoids, topical antibiotics, oral antibiotics, and in severe cases isotretinoin have all been used effectively in this population. Spironolactone, which is commonly used for acne in cisgender women due to its anti-androgenic properties, is typically avoided in transmasculine patients because it counteracts testosterone effects. A dermatologist familiar with transgender care will know this. Not all dermatologists are equally familiar, so asking upfront is reasonable.

Bottom line on this video

This is one of the better pieces of health content on testosterone-related acne you'll find on TikTok. A credentialed dermatologist, appropriate hedging on data quality, and practical clinical guidance without overreach. The severity statistic is presented with slightly more confidence than the evidence strictly supports, but the creator's own caveat about limited data partially addresses that. No dangerous claims, no prescribing, no red flags.